jingwen yin

Jingwen Yin has extensive work experience in the field of biomedicine and biological studies. From 2012 to 2014, they worked as a Postdoc at the Chinese Academy of Sciences, focusing on the development of disease-mouse models to understand the function of Med23 in disease development. This work resulted in publications in Cell Discovery and the EMBO journal. They then moved on to the Salk Institute for Biological Studies, where from 2014 to 2021, they held roles as a Postdoc and Sr. Postdoc. During this time, they conducted research on various projects, including gene knock-out/knock-in by CRISPR and the development of genetically-encoded nanoantibody-derived nanoparticle probes for in vivo targeting of proteins, DNA, or RNA. Their work involved using advanced imaging techniques such as fluorescence microscopy and electron microscopy. Most recently, starting in 2022, they joined Harbour Biomed as a Sr. Principal Scientist I, where they are responsible for evaluating new targets and leading the progress of new projects, with a focus on mono- or bi-specific antibody drug development.

Jingwen Yin began their education in 2001 at Jilin University, where they earned a Bachelor's degree in Bio-pharmaceutical Engineering in 2005. They then pursued further education at the Chinese Academy of Sciences' Shanghai Institute of Biochemistry and Cell Biology. From 2005 to 2012, Jingwen Yin completed a Doctor of Philosophy (Ph.D.) degree in Molecular Biology and Biochemistry.